REPLIGEN CORP Business Combination, Consideration Transferred, Equity Interests Issued and Issuable
REPLIGEN CORP (RGEN) reported Business Combination, Consideration Transferred, Equity Interests Issued and Issuable of $53.94 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-26.
Discontinued › Notes › Business Combinations › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation › Business Combination, Consideration Transferred
us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable · last filed 2020-02-26
- REPLIGEN CORP business combination, consideration transferred, equity interests issued and issuable for the quarter ending 2019-12-31 was $0.00.
- REPLIGEN CORP business combination, consideration transferred, equity interests issued and issuable for the quarter ending 2019-09-30 was $0.00.
- REPLIGEN CORP business combination, consideration transferred, equity interests issued and issuable for fiscal 2019 was $53.94M.
- REPLIGEN CORP business combination, consideration transferred, equity interests issued and issuable for fiscal 2017 was $247.57M, a 1651.50% increase from fiscal 2016.
- REPLIGEN CORP business combination, consideration transferred, equity interests issued and issuable for fiscal 2016 was $14.13M.
| Period end | Business Combination, Consideration Transferred, Equity Interests Issued and Issuable | Business Combination, Consideration Transferred, Equity Interests Issued and Issuable 3 month | Business Combination, Consideration Transferred, Equity Interests Issued and Issuable 6 month | Business Combination, Consideration Transferred, Equity Interests Issued and Issuable 9 month | Business Combination, Consideration Transferred, Equity Interests Issued and Issuable 12 month |
|---|---|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $0.00 derived: sum of 2 quarters · filed 2020-02-26 | $53.94M 10-K · filed 2020-02-26 | ||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $53.94M 10-Q · filed 2019-10-31 | |||
| 2019-06-30 | $53.94M 10-Q · filed 2019-08-01 | ||||
| 2017-12-31 | $247.57M 10-K · filed 2020-02-26 | ||||
| 2016-12-31 | $14.13M 10-K · filed 2019-03-01 | ||||
| 2014-06-02 | $4.00M 10-K · filed 2016-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |